Date Range
Date Range
Date Range
We study the primary cilium, a surface-exposed organelle required for vision, olfaction and developmental signaling and whose dysfunction leads to. 8203; obesity, skeletal malformations and kidney cysts. To decode the fundamental principles of ciliary trafficking and to understand. How trafficking shapes signaling at the primary cilium, we leverage. A broad expertise in biochemistry, proteomics, cell biology and in vitro reconstitution.
CytomX is a biotechnology company changing the landscape of antibody therapeutics with highly targeted Probody therapeutics. We are developing a pipeline of Probody therapeutics to treat cancer. We are led by a seasoned management team with deep experience in antibody drug development and cancer biology. Has the power to significantly expand the opportunity for therapeutic antibodies in oncology by addressing the limitations of existing technologies.
Quality Assurance and GMP Support. The European Chemicals Agency ECHA established a new website for consumers. News updates from EMA during February and March 2018. News updates from HMA during February and March 2018.
Developing Diagnostics and Therapeutics for Musculoskeletal Disease. Our mission is to be the leader in diagnostic products for musculoskeletal disease, and to develop highly effective biotechnology based treatments for osteoarthritis, back and joint pain. Therapy for knees that may restore ability to run and jump. Enrolling First Patient in A2M Therapy Study.
Manufacturer of hydrophobic and oleophobic coatings, additives and inks. Manufacturer of hydrophobic and oleophobic coatings, additives and inks. Cytonix was founded in 1985 and is located in Maryland, USA. Cytonix manufactures many superhydrophobic, hydrophobic and oleophobic coatings and coating-additives used in life-sciences, electronics, aerospace and communications industries. Hydrophobic conformal coatings for circuit boards. Cytonix introduced FluorAcryl 7298, a.